



November 13, 2025

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400051.
Symbol: RAINBOW

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Scrip Code: 543524

Sub: Outcome of the Board Meeting.

Ref: Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Dear Sir/ Madam,

In furtherance to our letter dated November 7, 2025, please take note that the Board of Directors of the Company, in their meeting held today i.e., November 13, 2025, has inter-alia considered and approved the following matters:

1. Financial Results:

The Unaudited Standalone and Consolidated Financial Results ("**Financial Results**") of the Company for the Quarter and Half Year ended September 30, 2025. A copy of the signed Results along with Limited Review Report issued by the Statutory Auditors M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, are enclosed as **Annexure - A**.

2. Appointment of Chief Executive Officer (Key Managerial Personnel) of the Company:

Upon the recommendation of the Nomination and Remuneration Committee, the Board of Directors has appointed Mr. Abrarali Dalal as the Chief Executive Officer (Key Managerial Personnel) of the Company with effect from January 20, 2026.

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad- 500034, Telangana
CIN:L85110TG1998PLC029914

Corporate Office: 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad- 500034, Telangana
info@rainbowhospitals.in 1800 2122 www.rainbowhospitals.in

OUR PRESENCE: BENGALURU | CHENNAI | DELHI | HYDERABAD | VIJAYAWADA | VISAKHAPATNAM | WARANGAL



The requisite disclosure as per Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as “**Annexure - B**” to this letter.

The Board Meeting commenced at 2:00 PM and concluded at 4:00 PM.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Rainbow Children's Medicare Limited**

Shreya Mitra
Company Secretary and Compliance Officer

Encl.: As above

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad- 500034, Telangana
CIN:L85110TG1998PLC029914

Corporate Office: 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad- 500034, Telangana

info@rainbowhospitals.in

1800 2122

www.rainbowhospitals.in

OUR PRESENCE: BENGALURU | CHENNAI | DELHI | HYDERABAD | VIJAYAWADA | VISAKHAPATNAM | WARANGAL

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

THE SKYVIEW 10
18th Floor, "NORTH LOBBY"
Survey No. 83/1, Raidurgam
Hyderabad - 500 032, India

Tel : +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


**Review Report to
The Board of Directors
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Rainbow Children's Medicare Limited (the "Company") for the quarter ended 30 September 2025 and year to date from 01 April 2025 to 30 September 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


per Atin Bhargava
Partner
Membership No.: 504777




UDIN: 25504777BMOCQU7673

Place: Hyderabad

Date: 13 November 2025

Rainbow Children's Medicare Limited						
CIN: L85110TG1998PLC029914						
Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034						
Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in						
Statement of Unaudited Standalone Financial Results for the quarter and year to date ended 30 September 2025						
Particulars	(Rs. in Millions except per share data)					
	Quarter ended			Year to date ended		Year ended
	30 September 2025	30 June 2025	30 September 2024	30 September 2025	30 September 2024	31 March 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income						
a. Revenue from operations	4,084.96	3,347.48	4,039.25	7,432.44	7,189.48	14,545.07
b. Other income	81.73	192.85	107.24	274.58	222.06	489.49
Total income	4,166.69	3,540.33	4,146.49	7,707.02	7,411.54	15,034.56
2. Expenses						
a. Cost of materials consumed	560.93	439.50	521.96	1,000.43	934.57	1,898.69
b. Employee benefits expense	532.74	492.36	515.11	1,025.10	985.66	1,976.08
c. Finance costs	173.09	173.93	173.89	347.02	348.28	695.94
d. Depreciation and amortisation expense	331.82	325.93	332.23	657.75	656.61	1,317.48
e. Professional fees to doctors	966.26	867.81	899.84	1,834.07	1,697.60	3,484.90
f. Other expenses	617.85	552.60	667.50	1,170.45	1,236.57	2,440.64
Total expenses	3,182.69	2,852.13	3,110.53	6,034.82	5,859.29	11,813.73
3. Profit before tax [1-2]	984.00	688.20	1,035.96	1,672.20	1,552.25	3,220.83
4. Tax expenses						
a. Current tax	280.20	168.65	291.22	448.85	442.60	856.68
b. Deferred tax	(27.87)	5.81	(25.40)	(22.06)	(47.76)	(31.54)
c. Adjustment of tax relating to earlier periods	-	(3.46)	(3.30)	(3.46)	(3.30)	19.84
Total tax expense	252.33	171.00	262.52	423.33	391.54	844.98
5. Profit after tax [3-4]	731.67	517.20	773.44	1,248.87	1,160.71	2,375.85
6. Other comprehensive income						
Items that will not be reclassified subsequently to the Statement of Profit or Loss						
a. Re-measurement (loss) / gain on defined benefit obligation	(0.72)	(0.72)	7.40	(1.44)	8.61	(2.88)
b. Income tax effect	0.18	0.18	(1.87)	0.36	(2.17)	0.72
Other comprehensive income (net of tax)	(0.54)	(0.54)	5.53	(1.08)	6.44	(2.16)
7. Total comprehensive income [5+6]	731.13	516.66	778.97	1,247.79	1,167.15	2,373.69
8. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.59	1,015.52	1,015.52	1,015.59	1,015.52	1,015.52
9. Other equity						13,869.92
10. Earning per share (Face value of Rs.10 each)						
a. Basic (Rs)	7.20	5.09	7.62	12.30	11.43	23.40
b. Diluted (Rs)	7.20	5.09	7.62	12.30	11.43	23.27
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- 1 The above statement of unaudited standalone financial results of Rainbow Children's Medicare Limited ("the Company"), which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 November 2025. The statutory auditors have carried out a limited review on the unaudited standalone financial results and issued an unmodified report thereon.
- 2 The Company has allotted 7,483 equity shares of Rs. 10 each, consequent to the exercise of the stock options by an eligible employee of the Company under the Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023 ("Stock Unit Plan 2023"). The allotment has been approved by the Nomination and Remuneration committee on 12 August 2025.
- 3 Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option.

The Nomination and Remuneration Committee ("NRC") of the Company in its meeting held on 13 November 2025, granted 5,660 Stock options under the ESOP 2025 to its eligible employees which shall be exercisable into 5,660 equity shares having face value of Rs.10 each fully paid-up. The Exercise price per stock option shall be determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, being the stock exchange with the highest trading volume, as on 13 November 2025 i.e., the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options shall vest after the minimum vesting period of 1 year and not later than the maximum period of 10 years from the date of grant. The vested Stock options shall be exercisable within a period of maximum of 2 years from the date of each vesting.

- 4 Pursuant to Securities Subscription Agreement ("SSA") and Shareholders Agreement ("SHA") dated 28 June 2025, the Company has acquired 76% of equity share capital and 100% of Non-Convertible Redeemable Preference shares of M/s. Prashanthi Medicare Private Limited ("Prashanthi Hospital") for an aggregate cash consideration of Rs. 326.00 million. Consequent to this acquisition, Prashanthi Hospital became a subsidiary of the Company with effect from 01 July 2025 upon satisfactory completion of the closing conditions under the SSA.
- 5 Pursuant to Securities Subscription Agreement ("SSA") and Shareholders Agreement ("SHA") dated 11 August 2025, the Company has acquired 76% of equity share capital and 100% of Non-Convertible Redeemable Preference shares of M/s. Pratiksha Women & Child Care Hospital Private Limited ("Pratiksha Hospital") for an aggregate cash consideration of Rs. 1,710.00 million. Consequent to this acquisition, Pratiksha Hospital became a subsidiary of the Company with effect from 18 August 2025 upon satisfactory completion of the closing conditions under the SSA.
- 6 The Company is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the Company are concentrated in India, and hence, the Company is considered to operate only in one geographical segment.
- 7 The standalone financial results for the quarter and year to date ended 30 September 2025, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nscindia.com) and on the Company's website (URL: www.rainbowhospitals.in).

for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited



Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 13 November 2025

Standalone Balance Sheet
(Rs. in Millions)

Particulars	As at	
	30 September 2025	31 March 2025
	Unaudited	Audited
ASSETS		
Non-current assets		
a. Property, plant and equipment	8,058.35	7,995.63
b. Capital work-in-progress	518.13	276.69
c. Right-of-use of assets	5,342.59	5,579.54
d. Intangible assets	97.75	102.42
e. Intangible assets under development	16.98	6.93
f. Financial assets		
(i) Investments	2,176.99	465.45
(ii) Loans	622.86	299.54
(iii) Other financial assets	295.76	310.42
g. Deferred tax assets (net)	308.35	285.94
h. Non-current tax assets (net)	99.85	99.86
i. Other non-current assets	475.74	264.76
Total non-current assets	18,013.35	15,687.18
Current assets		
a. Inventories	304.26	227.42
b. Financial assets		
(i) Investments	3,880.29	5,495.01
(ii) Trade receivables	1,077.20	784.62
(iii) Cash and cash equivalents	162.08	168.90
(iv) Bank balances other than (iii) above	0.20	0.20
(v) Loans	57.36	30.45
(vi) Other financial assets	1,088.86	981.96
c. Other current assets	199.24	166.46
Total current assets	6,769.49	7,855.02
TOTAL ASSETS	24,782.84	23,542.20
EQUITY AND LIABILITIES		
EQUITY		
a. Equity share capital	1,015.59	1,015.52
b. Other equity	14,819.59	13,869.92
TOTAL EQUITY	15,835.18	14,885.44
LIABILITIES		
Non-current liabilities		
a. Financial liabilities		
(i) Lease liabilities	7,053.82	7,147.05
b. Provisions	109.52	94.25
Total non-current liabilities	7,163.34	7,241.30
Current liabilities		
a. Financial liabilities		
(i) Lease liabilities	214.38	196.50
(ii) Trade payables		
a) Total outstanding dues to micro enterprises and small enterprises	106.33	91.16
b) Total outstanding dues to creditors other than micro enterprises and small enterprises	1,021.95	767.62
(iii) Other financial liabilities	202.76	169.66
b. Other current liabilities	144.16	125.26
c. Provisions	65.26	65.26
d. Current tax liabilities (net)	29.48	-
Total current liabilities	1,784.32	1,415.46
TOTAL EQUITY AND LIABILITIES	24,782.84	23,542.20



Standalone Statement of Cash Flows		
	(Rs. in Millions)	
Particulars	For the year to date ended 30 September 2025	For the year to date ended 30 September 2024
	Unaudited	Unaudited
Cash flows from operating activities		
Profit before tax	1,672.20	1,552.25
Adjustments:		
Depreciation and amortisation expense	657.75	656.61
Gain on redemption of mutual funds	(182.70)	(22.21)
Net gain on financial assets measured at fair value through profit or loss	(18.02)	(133.63)
Unrealised foreign exchange loss, net	-	0.36
Interest income on financial assets carries at amortised cost	(61.78)	(65.52)
Employee share based payment expense	6.54	(17.63)
Finance cost	347.02	348.28
Bad debts written off	1.04	-
(Reversal) / allowance for expected credit loss	(24.84)	44.01
Net gain on sale of property, plant and equipment	(11.86)	(0.42)
Liabilities no longer required written back	-	(0.27)
	2,385.35	2,361.83
Adjustments for working capital:		
Increase in inventories	(76.84)	(22.69)
Increase in trade receivables	(268.78)	(303.90)
Increase in financial and other assets	(21.68)	(6.01)
Increase in trade payables	269.49	216.16
Increase in financial and current liabilities	29.23	6.29
Increase in provisions	13.83	44.87
Cash generated from operations	2,330.60	2,296.55
Income tax paid, net	(415.90)	(404.07)
Net cash from operating activities (A)	1,914.70	1,892.48
Cash flows from investing activities		
Purchase of property, plant and equipment, intangibles, intangible assets under development including capital advances, capital creditors and capital work-in-progress	(927.37)	(794.31)
Proceeds from sale of property, plant and equipment	12.77	0.42
Investments in unquoted equity instruments of subsidiary companies	(1,548.12)	-
Investment in Non convertible redeemable preference share of subsidiary companies	(487.88)	-
Bank deposits invested with maturity of more than three months	(69.81)	(757.89)
Bank deposits redeemed with maturity of more than three months	22.91	1,226.76
Interest received	17.14	110.12
Gain on redemption of mutual funds, net	182.70	22.21
Investment in mutual funds	(3,439.94)	(4,114.79)
Redemption of mutual funds	5,072.68	3,185.95
Loans given	(30.00)	-
Loans realised	2.00	-
Net cash used in investing activities (B)	(1,192.92)	(1,121.53)
Cash flows from financing activities		
Payment of lease liabilities	(424.02)	(405.99)
Proceeds from issue of share capital	0.07	0.50
Dividend paid	(304.65)	(304.64)
Net cash used in financing activities (C)	(728.60)	(710.13)
Net increase in cash and cash equivalents (A+B+C)	(6.82)	60.82
Cash and cash equivalents at the beginning of the period	168.90	74.85
Cash and cash equivalents at the end of the period (note a)	162.08	135.67
Notes:		
a) Components of cash and cash equivalents	As at 30 September 2025	As at 30 September 2024
Cash on hand	6.05	6.65
Balance with banks:		
- Current accounts	156.03	84.02
- On deposit accounts (with original maturity of 3 months or less)	-	45.00
	162.08	135.67



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited (the "Holding Company"), its subsidiaries and other consolidating entity (the Holding Company, its subsidiaries and other consolidating entity together referred to as "the Group") for the quarter ended 30 September 2025 and year to date from 01 April 2025 to 30 September 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Holding Company:

Rainbow Children's Medicare Limited

Subsidiaries:

- a. Rainbow Speciality Hospitals Private Limited
- b. Rosewalk Healthcare Private Limited
- c. Rainbow C R O Private Limited
- d. Rainbow Fertility Private Limited
- e. Rainbow Children's Hospital Private Limited
- f. Rainbow Woman & Children's Hospital Private Limited
- g. Prashanthi Medicare Private Limited (with effect from 01 July 2025)
- h. Pratiksha Women & Child Care Hospital Private Limited (with effect from 18 August 2025)

Other Consolidating Entity:

Rainbow Children's Hospital Foundation

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results in respect of 6 subsidiaries, whose unaudited interim financial results include total assets of Rs 812.80 million as at 30 September 2025, total revenues of Rs 200.83 million and Rs 393.43 million, total net profit after tax of Rs 16.62 million and Rs 37.44 million, total comprehensive income of Rs 17.01 million and Rs 38.21 million, for the quarter ended 30 September 2025 and the period ended on that date respectively, and net cash inflows of Rs 0.87 million for the period from 01 April 2025 to 30 September 2025, as considered in the Statement which have been reviewed by their respective independent auditors.


The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


per Atin Bhargava
Partner
Membership No.: 504777



UDIN: 25504777BM0CQV7729

Place: Hyderabad

Date: 13 November 2025

Rainbow Children's Medicare Limited CIN: L85110TG1998PLC029914 Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034 Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in						
Statement of Unaudited Consolidated Financial Results for the quarter and year to date ended 30 September 2025						
Particulars	Quarter ended			Year to date ended		Year ended
	30 September 2025	30 June 2025	30 September 2024	30 September 2025	30 September 2024	31 March 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income						
a. Revenue from operations	4,447.99	3,529.29	4,174.60	7,977.28	7,476.77	15,158.66
b. Other income	81.95	200.16	112.73	282.11	232.07	510.08
Total income	4,529.94	3,729.45	4,287.33	8,259.39	7,708.84	15,668.74
2. Expenses						
a. Cost of materials consumed	622.14	474.98	516.72	1,097.12	941.51	1,949.20
b. Employee benefits expense	587.80	516.20	537.47	1,104.00	1,027.45	2,063.67
c. Finance costs	188.49	180.78	181.02	369.27	362.64	724.55
d. Depreciation and amortisation expense	358.41	341.87	349.00	700.28	690.43	1,384.40
e. Professional fees to doctors	1,063.19	917.58	952.26	1,980.77	1,801.90	3,690.21
f. Other expenses	686.21	584.30	697.34	1,270.51	1,297.86	2,556.70
Total expenses	3,506.24	3,015.71	3,233.81	6,521.95	6,121.79	12,368.73
3. Profit before tax [1-2]	1,023.70	713.74	1,053.52	1,737.44	1,587.05	3,300.01
4. Tax expenses						
a. Current tax	292.64	174.82	293.94	467.46	450.47	873.08
b. Deferred tax	(25.18)	4.33	(27.17)	(20.85)	(47.45)	(35.19)
c. Adjustment of tax relating to earlier periods	-	(3.46)	(3.30)	(3.46)	(3.30)	19.85
Total tax expense	267.46	175.69	263.47	443.15	399.72	857.74
5. Profit after tax [3-4]	756.24	538.05	790.05	1,294.29	1,187.33	2,442.27
6. Other comprehensive income						
Items that will not be reclassified subsequently to the Statement of Profit or Loss						
a. Re-measurement (loss)/gain on defined benefit obligation	(0.25)	(0.24)	7.51	(0.49)	8.85	(0.98)
b. Income tax effect	0.09	0.09	(1.87)	0.18	(2.18)	0.37
Other comprehensive income (net of tax)	(0.16)	(0.15)	5.64	(0.31)	6.67	(0.61)
7. Total comprehensive income [5+6]	756.08	537.90	795.69	1,293.98	1,194.00	2,441.66
Profit after tax attributable to						
Owners of the Company	752.50	534.99	788.69	1,287.49	1,184.02	2,434.24
Non-controlling interests	3.74	3.06	1.36	6.80	3.31	8.03
Profit after tax	756.24	538.05	790.05	1,294.29	1,187.33	2,442.27
Other comprehensive income attributable to						
Owners of the Company	(0.18)	(0.21)	5.63	(0.39)	6.66	(0.83)
Non-controlling interests	0.02	0.06	0.01	0.08	0.01	0.22
Other comprehensive income	(0.16)	(0.15)	5.64	(0.31)	6.67	(0.61)
Total comprehensive income attributable to						
Owners of the Company	752.32	534.78	794.32	1,287.10	1,190.68	2,433.41
Non-controlling interests	3.76	3.12	1.37	6.88	3.32	8.25
Total comprehensive income	756.08	537.90	795.69	1,293.98	1,194.00	2,441.66
8. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.59	1,015.52	1,015.52	1,015.59	1,015.52	1,015.52
9. Other equity						13,666.41
10. Earning per share (Face value of Rs.10 each)						
a. Basic (Rs)	7.41	5.27	7.77	12.68	11.66	23.97
b. Diluted (Rs)	7.41	5.27	7.77	12.68	11.66	23.84
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- 1 The above statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited ("the Company"), its subsidiaries and other consolidating entity (the Company, its subsidiaries and other consolidating entity together referred to as "the Group") which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 November 2025. The statutory auditors have carried out a limited review on the unaudited consolidated financial results and issued an unmodified report thereon.
- 2 The Company has allotted 7,483 equity shares of Rs. 10 each, consequent to the exercise of the stock options by an eligible employee of the Company under the Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023 ("Stock Unit Plan 2023"). The allotment has been approved by the Nomination and Remuneration committee on 12 August 2025.
- 3 Pursuant to the resolutions passed by the Board of Directors on 09 February 2025 and by the Shareholders on 02 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025") in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option.

The Nomination and Remuneration Committee ("NRC") of the Company in its meeting held on 13 November 2025, granted 5,660 Stock options under the ESOP 2025 to its eligible employees which shall be exercisable into 5,660 equity shares having face value of Rs.10 each fully paid-up. The Exercise price per stock option shall be determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, being the stock exchange with the highest trading volume, as on 13 November 2025 i.e., the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options shall vest after the minimum vesting period of 1 year and not later than the maximum period of 10 years from the date of grant. The vested Stock options shall be exercisable within a period of maximum of 2 years from the date of each vesting.

- 4 Pursuant to Securities Subscription Agreement ('SSA') and Shareholders Agreement ('SHA') dated 28 June 2025, the Company has acquired 76% of equity share capital and 100% of Non-Convertible Redeemable Preference shares of M/s. Prashanthi Medicare Private Limited ("Prashanthi Hospital") for an aggregate cash consideration of Rs 326.00 million. Consequent to this acquisition, Prashanthi Hospital became a subsidiary of the Company with effect from 01 July 2025 upon satisfactory completion of the closing conditions under the SSA and has been consolidated with effect from that date. The Group has completed the purchase price allocation and recognised Rs 122 million towards the fair value of net assets acquired, Rs 204 million towards Goodwill and Rs 79 million towards non-controlling interests.
- 5 Pursuant to Securities Subscription Agreement ('SSA') and Shareholders Agreement ('SHA') dated 11 August 2025, the Company has acquired 76% of equity share capital and 100% of Non-Convertible Redeemable Preference shares of M/s. Pratiksha Women & Child Care Hospital Private Limited ('Pratiksha Hospital') for an aggregate cash consideration of Rs. 1,710.00 million. Consequent to this acquisition, Pratiksha Hospital became a subsidiary of the Company with effect from 18 August 2025 upon satisfactory completion of the closing conditions under the SSA and has been consolidated with effect from that date. The transaction was accounted in accordance with Ind AS 103 and the initial accounting has been provisionally determined. The Group recognised Rs 339 million towards the fair value of net assets acquired, Rs 1,371 million towards Goodwill and Rs 413 million towards non-controlling interests.
- 6 The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- 7 The consolidated financial results for the quarter and year to date ended 30 September 2025, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).
- 8 The unaudited consolidated financial results include the financial results of Rainbow Children's Medicare Limited and the financial results of its subsidiaries, Rainbow C R O Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited, Rainbow Children's Hospital Private Limited, Prashanthi Medicare Private Limited, Pratiksha Women & Child Care Hospital Private Limited and its other consolidating entity, Rainbow Children's Hospital Foundation.


for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited




Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 13 November 2025

Consolidated Balance Sheet		
	(Rs. in Millions)	
Particulars	As at	
	30 September 2025	31 March 2025
	Unaudited	Audited
ASSETS		
Non-current assets		
a. Property, plant and equipment	8,390.69	8,132.82
b. Capital work-in-progress	526.71	277.66
c. Right-of-use of assets	6,123.69	5,745.33
d. Goodwill	1,575.68	-
e. Other intangible assets	395.74	103.28
f. Intangible assets under development	16.98	6.93
g. Financial assets		
(i) Investments	0.03	0.03
(ii) Loans	286.39	297.72
(iii) Other financial assets	315.09	319.74
h. Deferred tax assets (net)	320.87	295.89
i. Non-current tax assets (net)	145.25	103.68
j. Other non-current assets	491.56	266.25
Total non-current assets	18,588.68	15,549.33
Current assets		
a. Inventories	403.42	275.69
b. Financial assets		
(i) Investments	4,155.27	5,707.28
(ii) Trade receivables	1,073.30	773.01
(iii) Cash and cash equivalents	268.17	202.55
(iv) Bank balances other than (iii) above	0.20	0.20
(v) Loans	35.00	30.00
(vi) Other financial assets	1,120.12	1,054.70
c. Other current assets	222.38	177.10
Total current assets	7,277.86	8,220.53
TOTAL ASSETS	25,866.54	23,769.86
EQUITY AND LIABILITIES		
EQUITY		
a. Equity share capital	1,015.59	1,015.52
b. Other equity	14,163.86	13,666.41
Equity attributable to owners of the Company	15,179.45	14,681.93
Non-controlling interest	149.86	68.17
TOTAL EQUITY	15,329.31	14,750.10
LIABILITIES		
Non-current liabilities		
a. Financial liabilities		
(i) Lease liabilities	7,921.82	7,416.79
(ii) Other financial liabilities	416.74	-
b. Provisions	114.62	97.25
Total non-current liabilities	8,453.18	7,514.04
Current liabilities		
a. Financial liabilities		
(i) Lease liabilities	239.44	219.02
(ii) Trade payables		
a) Total outstanding dues to micro enterprises and small enterprises	106.33	102.02
b) Total outstanding dues to creditor other than micro enterprises and small enterprises	1,186.34	807.66
(iii) Other financial liabilities	259.18	178.07
b. Other current liabilities	157.34	131.99
c. Provisions	66.96	66.96
d. Deferred tax liabilities (net)	3.95	-
e. Current tax liabilities (net)	64.51	-
Total current liabilities	2,084.05	1,505.72
TOTAL EQUITY AND LIABILITIES	25,866.54	23,769.86



Consolidated Statement of Cash Flows		
	(Rs. in Millions)	
Particulars	For the year to date ended 30 September 2025	For the year to date ended 30 September 2024
	Unaudited	Unaudited
Cash flows from operating activities		
Profit before tax	1,737.44	1,587.05
Adjustments:		
Depreciation and amortisation expense	700.28	690.43
Gain on redemption of mutual funds	(190.41)	(26.86)
Unrealised foreign exchange loss, net	-	0.38
Net gain on financial assets measured at fair value through profit or loss	(18.02)	(133.63)
Interest income on financial assets carried at amortised cost	(59.59)	(69.98)
Finance costs	369.27	362.64
Employee share based payment expense	6.54	(17.63)
Advances written off	-	0.10
(Reversal) / allowance for expected credit loss	(21.44)	44.01
Bad debts written off	1.42	-
Net gain on sale of property, plant and equipment	(11.86)	(0.42)
Liabilities no longer required written back	(2.01)	(1.18)
	2,511.62	2,434.91
Adjustments for working capital:		
Increase in inventories	(127.73)	(40.10)
Increase trade receivables	(280.27)	(288.14)
Increase in financial and other assets	(41.51)	(6.62)
Increase in trade payables	383.13	194.97
Increase in financial and current liabilities	54.81	0.12
Increase in provisions	16.88	45.38
Cash generated from operations	2,516.93	2,340.52
Income tax paid, net	(441.06)	(412.39)
Net cash from operating activities (A)	2,075.87	1,928.13
Cash flows from investing activities		
Purchase of property, plant and equipment, goodwill, other intangibles, intangible assets under development including capital advances, capital creditors and capital work-in-progress	(3,022.72)	(801.55)
Proceeds from sale of property, plant and equipment	12.77	0.42
Bank deposits invested with maturity of more than three months	(2,508.78)	(865.71)
Bank deposits redeemed with maturity of more than three months	2,489.94	1,397.59
Interest received	20.29	122.24
Gain on redemption of mutual funds, net	190.41	26.86
Investment in mutual funds	(3,499.94)	(4,211.79)
Redemption of mutual funds	5,069.97	3,189.32
Net cash used in investing activities (B)	(1,248.06)	(1,142.62)
Cash flows from financing activities		
Principal payment of lease liabilities	(457.62)	(429.19)
Dividend paid	(304.64)	(304.64)
Proceeds from issue of share capital	0.07	0.50
Net cash used in financing activities (C)	(762.19)	(733.33)
Net increase in cash and cash equivalents (A+B+C)	65.62	52.18
Cash and cash equivalents at the beginning of the period	202.55	101.19
Cash and cash equivalents at the end of the period (note a)	268.17	153.37
Notes:		
a) Components of cash and cash equivalents	As at 30 September 2025	As at 30 September 2024
Cash on hand	10.60	8.16
Balance with banks:		
- Current accounts	257.57	100.21
- On deposit accounts (with original maturity of 3 months or less)	-	45.00
	268.17	153.37



Annexure – B

S. No	Particulars	Details
		Mr. Abrarali Dalal
1.	Reasons for change viz appointment, resignation, removal, death or otherwise	Appointment as Chief Executive Officer (Key Managerial Personnel) of the Company
2.	Date of appointment/ Cessation & term of appointment.	Date of Appointment: January 20, 2026 Term of Appointment: Not Applicable
3.	Brief Profile (In case of Appointment)	Mr. Abrarali Dalal is a seasoned business leader with over 25 years of experience spanning healthcare and allied sectors. He has successfully led large, multi-location hospital networks through transformational growth journeys, driving scale, profitability, and operational excellence, while serving in multiple CXO roles and steering organizations from top leadership positions. Over the years, he has held progressive leadership roles across operations, strategy, and business development, with a proven track record in turnaround management, brownfield expansions, clinical excellence, and brand repositioning. His strategic focus has been on digital transformation, star clinician recruitment and retention, and productivity-led profitability improvement. Mr. Dalal is known for his sharp business acumen, people-first leadership, and ability to deliver strong investor outcomes through disciplined execution and value creation. He holds an MBA and a Diploma in Foreign Trade from reputed institutions in Pune, and a Bachelor's degree in Science.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad- 500034, Telangana
CIN:L85110TG1998PLC029914

Corporate Office: 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad- 500034, Telangana

info@rainbowhospitals.in 1800 2122 www.rainbowhospitals.in